SCHEMBL5952920

SCHEMBL5952920

CCC(=O)c1ccc(F)cc1Br

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2R P25116 2/20 0.48
HSP90AB1 P08238 1/20 0.46
PKM P14618 1/20 0.44
CES2 O00748 2/20 0.42
CES1 P23141 2/20 0.42
MAPT P10636 2/20 0.42
KCNH2 Q12809 1/20 0.40
POLB P06746 1/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CHRNA7 P36544 1/20 0.39
RAB9A P51151 1/20 0.38
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21780538 0.86 F2R (0.56) F2RPKMCES2CES1MAPT
SCHEMBL27583391 0.85 F2R (0.48) F2RHSP90AB1PKMCES2CES1
SCHEMBL31573474 0.83 PKM (0.45) F2RPKMCES2CES1MAPT
SCHEMBL30195364 0.83 PTPN1 (0.52) F2RPKMCES2CES1MAPT
SCHEMBL615669 0.83 PTPN1 (0.52) F2RPKMCES2CES1MAPT
SCHEMBL27560772 0.82 NPC1 (0.44) HSP90AB1PKMMAPTKCNH2ALDH1A1
SCHEMBL196379 0.81 CES2 (0.61) HSP90AB1PKMCES2CES1KCNH2
SCHEMBL6174178 0.81 HSP90AB1 (0.48) HSP90AB1CES2MAPTPOLBALDH1A1
SCHEMBL29746067 0.81 CES2 (0.61) HSP90AB1PKMCES2CES1KCNH2
SCHEMBL31582781 0.80 F2R (0.44) F2RPKMCES2CES1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107056673-B 3, 4-diaryl maleimide derivative and preparation method and application thereof NANJING TECH UNIVERSITY (CN) 2019-10-29 CN disclosed
CN-106432039-B 3, 4-diaryl maleimide derivative and preparation method and application thereof 南京工业大学 2019-02-22 CN disclosed
CN-108137497-A Bicyclic derivatives, process for their preparation and pharmaceutical compositions containing them 法国施维雅药厂 2018-06-08 CN disclosed
CN-104837844-B Pyrazole substituted imidazopiperazines as casein kinase 1D/E inhibitors 百时美施贵宝公司 2017-08-29 CN disclosed
CN-107056673-A 3, 4-diaryl maleimide derivative and preparation method and application thereof 南京工业大学 2017-08-18 CN disclosed
CN-106946909-A The nitro imidazole derivatives for the treatment of pulmonery tuberculosis disease 南京明德新药研发股份有限公司 2017-07-14 CN disclosed
CN-106232600-A Dihydroindole 2 ketone and 1,3 pyrrolin also [3,2 c] pyridine 2 ketone derivatives 豪夫迈·罗氏有限公司 2016-12-14 CN disclosed
CN-105801571-A Heterocyclic difluoromethylated oxirane compound and preparation method thereof 上海大学 2016-07-27 CN disclosed
CN-105814039-A Fluorophenyl pyrazole compounds 伊莱利利公司 2016-07-27 CN disclosed
CN-103360305-A Substituted aryl piperazine aralkyl ketone derivative and application of derivative in preparing analgesic JIANGSU NHWA PHARMACEUTICAL CO LTD 2013-10-23 CN disclosed
CN-1191254-C Fused pyrrole compounds, pharmaceutical composition containing the same, and the use thereof MARCKLE GMBH (DE) 2005-03-02 CN disclosed
US-20050033076-A1 Preparation of preparing substituted indanones EQUISTAR CHEMICALS, LP 2005-02-10 US disclosed
CN-1518550-A Imidazo [1,2-A] pyridine derivatives for prophylaxis and treatment of herpes viral infections ʷ��˿�������ȳ�ķ���޹�˾ 2004-08-04 CN disclosed
CN-1418217-A Fused pyrrole compounds, pharmaceutical composition containing the same, and the use thereof MARCKLE GMBH (DE) 2003-05-14 CN disclosed
US-20030009046-A1 Preparation of preparing substituted indanones EQUISTAR CHEMICALS, LP 2003-01-09 US disclosed
CN-1306511-A Novel heterocyclic compounds NOVO NORDISK AS (DK) 2001-08-01 CN disclosed
CN-1254328-A Process for preparing substituted 2, 3-dihydro-1-indanones TARGOR GMBH (DE) 2000-05-24 CN disclosed
EP-0968158-A1 METHOD OF PREPARING SUBSTITUTED INDANONES, THE SUBSTITUTED INDANONES AND METALLOCENES PREPARED THEREFROM Basell Polyolefine GmbH (DE) 2000-01-05 EP disclosed
WO-1998040331-A1 PREPARATION OF PREPARING SUBSTITUTED INDANONES TARGOR GMBH (DE) 1998-09-17 WO disclosed
CN-1115761-A Derivative, preparation and medical application of quinoline and imidazole SYNTHELABO (FR) 1996-01-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050033076-A1 Preparation of preparing substituted indanones CYP1A2, CYP2J2, IDH3A F2R 2373/4885HSP90AB1 2881/4885PKM 601/4885
US-20030009046-A1 Preparation of preparing substituted indanones CYP1A2, CYP1B1, CYP1A1 F2R 2214/4885HSP90AB1 2643/4885PKM 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.